After a half-century of attempts, psilocybin has finally been synthesized in the lab

August 16, 2017 by Bob Yirka, Medical Xpress report
Credit: CC0 Public Domain

A team of researchers at Friedrich Schiller University Jena has figured how out to make psilocybin, the chemical responsible for creating hallucinations in people who consume the mushrooms that produce it naturally. In their paper published in the journal Angewandte Chemie the team describes isolating the enzymes needed to create the chemical, developing the recipe and creating psilocybin samples in their lab.

People have known of the hallucinogenic effects of eating certain "magic mushrooms" for hundreds or even thousands of years. But it took Albert Hofman's efforts to isolate the psychoactive ingredients in 1958. Since that time, many scientists have tried to figure out how, exactly, mushrooms make so that it can be artificially synthesized and sold as a medicinal drug. Attempts have failed until now. Notably, growing magic mushrooms for commercial use has proven difficult due to the unique attributes of the mushrooms.

To learn how mushrooms naturally create psilocybin, the researchers sequenced the genomes of two of the main types of magic —that allowed them to isolate the genes that were responsible for producing the enzymes that lead to the creation of psilocybin. Next, they engineered fungi and bacteria samples to confirm their initial findings and to learn of the order in which the synthesis took place. As it turned out, there were four enzymes involved in the process, but after more study, the researchers found that only three of them (PsiD, PsiK, and PsiM) were needed to make the chemical in the lab.

Using this information, the researchers developed a "one pot reaction" recipe for creating psilocybin on demand, utilizing the enzymes they had isolated. They then created samples of psilocybin in their lab—the first team ever to do so.

Their efforts may pave the way for commercial production of psilocybin as a pharmaceutical drug for use in treating such as depression or anxiety, or even for smoking cessation.

Explore further: Active ingredient in magic mushrooms reduces anxiety and depression in cancer patients

More information: Janis Fricke et al. Enzymatic synthesis of psilocybin, Angewandte Chemie International Edition (2017). DOI: 10.1002/anie.201705489

Related Stories

Active ingredient in magic mushrooms reduces anxiety and depression in cancer patients

December 10, 2015
A single dose of psilocybin, the major hallucinogenic component in magic mushrooms, induces long-lasting decreases in anxiety and depression in patients diagnosed with life-threatening cancer according to a new study presented ...

Researchers urge caution around psilocybin use

December 30, 2016
In a survey of almost 2,000 people who said they had had a past negative experience when taking psilocybin-containing "magic mushrooms," Johns Hopkins researchers say that more than 10 percent believed their worst "bad trip" ...

Magic mushroom compound psilocybin could provide new avenue for antidepressant research

May 17, 2016
Psilocybin - a hallucinogenic compound derived from magic mushrooms - may offer a possible new avenue for antidepressant research, according to a new study published in The Lancet Psychiatry today.

Psilocybin reduces psychological pain after social exclusion

April 18, 2016
Social problems are key characteristics in psychiatric disorders and are insufficiently targeted by current treatment approaches. By applying brain imaging methods, researchers at the University of Zurich now show that a ...

fMRI brain imaging illuminates magic mushrooms' psychedelic effects

January 23, 2012
Brain scans of people under the influence of the psilocybin, the active ingredient in magic mushrooms, have given scientists the most detailed picture to date of how psychedelic drugs work. The findings of two studies being ...

Recommended for you

Researchers illustrate how muscle growth inhibitor is activated, could aid in treating ALS

January 19, 2018
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for ...

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

Weight flux alters molecular profile, study finds

January 17, 2018
The human body undergoes dramatic changes during even short periods of weight gain and loss, according to a study led by researchers at the Stanford University School of Medicine.

Secrets of longevity protein revealed in new study

January 17, 2018
Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure ...

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Magnetically applied MicroRNAs could one day help relieve constipation

January 17, 2018
Constipation is an underestimated and debilitating medical issue related to the opioid epidemic. As a growing concern, researchers look to new tools to help patients with this side effect of opioid use and aging.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.